雅虎香港財經 FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) results.
Bristol Myers Squibb added adagrasib via its $5 billion Mirati Therapeutics Inc. deal.
The approval is based on results from cohorts of the Phase 1/2 KRYSTAL-1 open-label study, which evaluated Krazati (600 mg tablets administered orally twice daily) in combination with cetuximab in 94 patients with heavily pretreated CRC harboring a KRASG12C mutation.
The study met its primary endpoint, with a confirmed ORR of 34% for Krazati with cetuximab, all of which were partial responses.
The median DOR, one of the secondary endpoints, was 5.8 months.
Current late-line standard of care options results in limited response rates (ORR 1-6%) after progression on chemotherapy ± VEGF/VEGFR inhibitors.
The company partnered with QIAGEN NV (NYSE:QGEN) to develop a tissue-based companion diagnostic (CDx) for Krazati that is now available.
The company added that Krazati is associated with the following Warnings & Precautions: Gastrointestinal adverse reactions including diarrhea, nausea, and vomiting, QTc interval prolongation, hepatotoxicity, and interstitial lung disease (ILD)/pneumonitis.
In 2022, Krazati was granted accelerated approval for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, who have received at least one prior systemic therapy.
Reuters, citing a Morning Star analyst, notes that “The approval helps justify Bristol’s decision to buy Mirati.” The analyst estimates just over a billion dollars in annual sales for Krazati.
Price Action: BMY shares are up 0.38% at $42.09 during the premarket session at last check Monday.
Photo via Shutterstock
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
